Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Breast Cancer
Interventions: DRUG: Trilaciclib|DRUG: Cylophosphamide|DRUG: Doxorubicin|DRUG: Paclitaxel|DRUG: Carboplatin (Investigator discretion)|BIOLOGICAL: Pembrolizumab (Investigator discretion)
Sponsor: G1 Therapeutics, Inc.